SetPoint Medical is a biomedical technology company developing bioelectronic therapies for patients with inflammatory autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease.

More than $30 billion is spent annually in the U.S. on biologic agents to treat rheumatoid arthritis and Crohn’s, yet a significant percentage of patients fail to get an adequate response or can’t tolerate biologic therapy.

The company’s scientific platform is based on the Inflammatory Reflex, the natural mechanism by which the central nervous system regulates the immune system. SetPoint co-founder Kevin Tracey discovered the Inflammatory Reflex pathway, publishing his findings in the journal Nature in May 2000.

SetPoint’s approach uses digital doses – targeted pulses of electricity – to activate the Inflammatory Reflex. Published literature demonstrates stimulation of the Inflammatory Reflex produces a potent systemic anti-inflammatory effect. SetPoint’s novel platform consists of an implantable pill-sized bioelectronic medicine device, wireless charger and iPad control application.

SetPoint successfully completed a first-in-human proof-of-concept trial in rheumatoid arthritis, which was published in the Proceedings of the National Academy of Sciences in 2016, and is currently conducting human trials in Crohn’s disease in multiple European centers.

SetPoint is headquartered in Valencia, Ca., and investors in the company include NEA, Morgenthaler Ventures, Topspin Partners, Boston Scientific, Medtronic and Action Potential Venture Capital.